Brief: Glenmark Pharma Says U.S. FDA Inspection At Co' Facility At Monroe
18/06/2025 06:43
June 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: U.S. FDA INSPECTION AT THE COMPANY'S FACILITY AT MONROE, NORTH CAROLINA, USA COMPANY WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS BY USFDA OBSERVATIONS ARE PROCEDURAL IN NATURE THERE WAS NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED Source text: [ID:] Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter